Taurine Spray Drying for Inhalation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for spray drying active pharmaceutical ingredients like taurine for inhalation face challenges with particle agglomeration, leading to reduced aerosol performance and stability issues, particularly with taurine which tends to form amorphous matrices and absorb moisture, causing physical instability.
Innovation Solution
Conditioned taurine is produced through a method involving zwitterionic neutralization during spray drying, controlling parameters such as pH, feedstock concentration, temperature, and T(solid:gas) ratio to prevent agglomeration, resulting in particles with a particle size of <20 μm and minimal moisture content, maintaining stability and aerosol performance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If taurine is spray dried using conventional methods, then it forms amorphous matrices, but this leads to hygroscopicity and particle agglomeration causing physical instability
Solution Approach 1:
The patent applies parameter changes by controlling spray drying conditions including feedstock temperature (20-70°C), outlet temperature (50-120°C), pH (adjusted to specific ranges), and T(solid:gas) ratio (2.000×10−6 to 2.750×10−3) to transform taurine from forming amorphous hygroscopic matrices to forming stable crystalline or controlled morphology particles with reduced agglomeration tendency
Solution Approach 2:
The patent utilizes phase transitions by controlling the crystallization behavior of taurine during spray drying, transitioning from amorphous to crystalline state through controlled cooling and drying conditions, which eliminates hygroscopicity and prevents particle agglomeration
2Reliability
If mannitol is used as excipient for spray drying, then it provides stabilizing capabilities and dries in crystalline state, but it induces coughing when administered via pulmonary route
Solution Approach 1:
The patent extracts or removes mannitol from the formulation by using taurine itself as the stabilizing excipient, eliminating the harmful cough-inducing property while maintaining the beneficial stabilizing and crystalline drying capabilities
Solution Approach 2:
The patent applies self-service by using taurine to stabilize itself during spray drying, where taurine acts as both the active ingredient and the stabilizing excipient, forming crystalline structures that provide stability without requiring external excipients like mannitol
3Stability of the object's composition
If trehalose is used as excipient for spray drying, then it prevents desiccation damage, but it forms amorphous matrices that are hygroscopic and cause particle agglomeration
Solution Approach 1:
The patent extracts trehalose from the formulation and replaces it with taurine, which provides similar protective capabilities against desiccation damage but without the harmful hygroscopicity and agglomeration issues associated with trehalose-based amorphous matrices
Solution Approach 2:
The patent changes the physical state parameter from amorphous to crystalline by using taurine's inherent crystallization properties during spray drying, which maintains desiccation protection while eliminating hygroscopicity and particle agglomeration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively prevents particle agglomeration and maintains the stability and aerosol performance of taurine particles, ensuring they remain respirable and chemically stable over time, addressing the limitations of existing spray drying techniques.
Implementation Method 1
Conditioned taurine is produced through a method involving zwitterionic neutralization during spray drying
Implementation Method 2
The process provides enhanced control over particle size, size distribution, particle shape, density, purity and structure
Implementation Method 3
The process of spray drying has been widely used in the production of pharmaceuticals since the 1940s
Data Source
AI summary
The invention discloses spray-dried compositions for inhalation and methods for preparing such powder compositions. The compositions of the invention are produced by spray-drying taurine under conditions that (i) retain the physical and chemical stability of the composition during spray drying and upon storage, (ii) protect the powder composition from aggregation and (iii) provide particles suitable for aerosolization.